£3 million fund to accelerate development of new cystic fibrosis therapies
LifeArc, as part of the CF AMR Syndicate, is providing £3 million in collaborative funding to drug discovery innovators to accelerate the development of new treatments for people with cystic fibrosis.
Overview
The call was for researchers in academia and small and medium enterprises (SMEs) worldwide with projects expected to last up to two years, and total funding of up to £500,000 per project.
Successful applicants will benefit from a truly collaborative approach to drug development, with access to expert advice and practical support from managing partners Medicines Discovery Catapult (MDC), LifeArc and Cystic Fibrosis Trust.
The CF Syndicate in AMR is a cross-sector initiative that brings together leading experts in CF and AMR from industry, academia and the clinic with people with CF to accelerate the translation of CF antimicrobials to the clinic and bring new and effective treatment options to people with CF. The Syndicate was established in 2019 and is jointly managed by Medicines Discovery Catapult, Cystic Fibrosis Trust and LifeArc.
Funding available
This fund is now closed to new applications.
Process and timelines
| Application step | Date |
|---|---|
| Call for expression of interest (EOI) opened: | 30 March 2023 |
| Call for expression of interest (EOI) closed: | 9 May 2023 |
| Workshop for shortlisted applicants: | June 2023 |
| Shortlisted applicants invited to full application | June 2023 |
| Full applications due: | 28 July 2023 |
| Final decision: | October 2023 |
| Project start date: | By the end of 2023 |
Contact us
In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. If you would like your data to be removed, please email dataprivacy@lifearc.org.
Please see our Privacy Policy in relation to the personal data you submit to us through this page.
Latest news
-
3 steps LifeArc is taking to tackle antimicrobial resistance before it’s too late
-
£76M investment backing into potential MND treatment, underlines benefit of charity funding
-
Tackling antimicrobial resistance: LifeArc partners with the University of Cape Town to launch a new Centre for Translational AMR Research